The numbers got uglier
Tissue Regenix said its FY24 adjusted EBITDA wasn’t a $1.9 million profit after all — it was a $1.0 million loss. And because the accounting gods love a sequel, H125 got dragged down too, flipping from a $0.2 million profit to a $2.3 million loss.
That’s the kind of restatement that makes investors squint at the spreadsheet and ask, “So… what else changed?” The company didn’t spell out every line-item culprit in the snippet, but the headline is clear: the earlier glow-up was a mirage.
New faces at the top
The board shake-up is just as dramatic. Daniel Lee is out as CEO, Jay LeCoque is stepping in as acting CEO while also serving as executive chairman, and Kirsten Lund is back as CFO with a mandate to tighten financial controls.
That’s corporate speak for: the board wants more discipline, fewer surprises, and probably fewer coffee-fueled budget “ideas.” For a small med-tech company, leadership stability can matter almost as much as the product pipeline.
Why investors should care
Tissue Regenix said it’s launching a cost-reduction plan worth more than $2 million, aiming to improve gross margins and EBITDA. That’s sensible on paper — especially with cash of just $1.1 million at June 30, 2025, and $10.4 million already drawn on debt facilities.
So the story here is less “growth rocket” and more “survival mode with a roadmap.” If management can cut costs without kneecapping sales, the company could buy itself some breathing room. If not, the balance sheet may keep calling the shots.
Big picture: This is a classic turnaround setup: restated numbers, a leadership reset, and a cost-cutting campaign. Useful cleanup? Sure. Easy fix? Not even close.